Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1988-04-13
1989-08-01
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514414, 514885, A61K 3140
Patent
active
048534099
ABSTRACT:
This invention relates to the use of certain 3-substituted-2-oxindole-1-carboxamides of the formula ##STR1## and the pharmaceutically-acceptable base salts thereof wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl to suppress T-cell function in a mammal. This invention also relates to the use of such compounds for treating T-cell mediated autoimmune disorders of the systemic or organ specific type. The methods of this invention comprise administering a T-cell function suppressing amount of the compounds and salts of this invention to such a mammal.
REFERENCES:
patent: 4556672 (1985-12-01), Kadin
patent: 4569942 (1986-02-01), Kadin
Bailey, J. M. et al., "Regulation of T-Lymphocyte Mitogenesis by the Leukocyte Product 15-Hydroxy-eicosatetraenoic Acid (15-HETE)", Cellular Immunology, 67, 112-120 (1982).
Kelly, J. P. et al., "Effect of Inhibitors of Arachidonic Acid Metabolism on Mitogenesis in Human Lymphocytes: Possible Role of Thromboxanes and Products of the Lipoxygenase Pathway", J. Immunology, 122, 1563-1571 (1979).
Leung, K. H. et al., "Modulation of the Development of Cell-Mediated Immunity: Possible Role of the Products of the Cyclo-oxygenase and the Lipoxygenase Pathways of Arachidonic Acid Metabolism", Int. J. Immunopharmac., 4, 195-204 (1982).
Crout, J. E. et al., "Suppression of Lymphocyte Transformation After Aspirin Ingestion", N.E.J. Med., 292, 221-223 (1975).
Bellanti, Joseph A., Immunology III, W. B. Saunders Co., Philadelphia (1985), Chapter 20, Part C, pp. 409-446.
Autoimmunity: Basic Concepts; Systemic and Selected Organ-Specific Diseases, Cruse, J. M. and Lewis, Jr., R. E., Eds., S. Karger, New York (1985), pp. 51-71.
Hanna, N. et al., "Cytokines: Targets for Novel Anti-Inflammatories: An Overview", Adv. Inflammation Res., vol. 12 (1988), pp. 11-14.
O'Flaherty, J. T. et al., "Neutrophil-Aggregating Activity of Monohydroxyeicosatetraenoic Acids", A.J.P., 104, 55.62 (1981).
Kunkel, S. L. et al., "Prostaglandins and the Regulation of Immune Responses", Adv. Inflammation Res., 7, 93-109 (1984).
Gordon, D. et al., "Control of Lymphokine Secretion by Prostaglandins", Nature, 262, 401-402 (1976).
Kunkel, S. L. et al., "Role of Lipoxygenase Products in Murine Pulmonary Granuloma Formation", J. Clin. Invest., 74, 514-524 (1984).
Pages 6-8 of the Presentation by Barry M. Bloom to Analysts of First Boston, New York City, New York on Sep. 10, 1987.
F-D-C Reports, Sep. 28, 1987, p. 11.
"Three Pfizer Drugs Promising; FDA Okay to Be Sought in '89", Chemical Marketing Reporter, Sep. 14, 1987, p. 7.
F-D-C Reports, Sep. 14, 1987, p. 2.
Benson Gregg C.
Gobrogge Roger
Lumb J. Trevor
Pfizer Inc.
Richardson Peter C.
LandOfFree
3-substituted-2-oxindole-1-carboxamides for suppressing T-cell f does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell f, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell f will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-131877